Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Bram PriemDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0009-0002-6793-816X
Lisa WillemsenDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes; Amsterdam Institute for Infection and Immunity, Inflammatory diseases, (AI&II), Amsterdam University Medical Centers, location University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-9676-9249
Tom AnbergenDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-7155-7709
Yuri van ElsasDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0009-0002-2985-3368
Jeroen DeckersDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0003-2723-8660
David P SchrijverLaboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID 0000-0002-2177-4836
Stijn R J HofstraatLaboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID 0000-0003-2120-5171
Iris V MessingDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0009-0000-3617-7199
Jazz MunitzBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-9173-2666
Dionne HoningDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0009-0009-3179-787X
Geoffrey PrévotBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-5191-9784
Yohana C TonerDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0001-5309-6366
Judit MorlaBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1059-6939
William WangBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anna RanzenigoBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Isabella SirchiaBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0009-0005-0789-7716
Tomas PostBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0350-6045
Raphaël DuivenvoordenBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1446-8336
Ewelina KluzaLaboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.
Glenn A O CremersTrained Therapeutix Discovery, 5349 AB Oss, Netherlands.
Joost H C M KreijtzTrained Therapeutix Discovery, 5349 AB Oss, Netherlands.ORCID 0000-0003-4180-7567
Carlos Pérez-MedinaBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6011-0629
Mandy M T van LeentBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abraham J P TeunissenBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0401-8262
Roy van der MeelLaboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID 0000-0002-2200-7946
Yi ZhouDepartment of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-4664-4317
Chris GlassDepartment of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jordi OchandoDepartment of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Tisch Cancer Institute at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7037-1681
Leo A B JoostenDepartment of Internal Medicine and Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0001-6166-9830
Zahi A FayadBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3439-7347
Romana T Netea-MaierDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-9603-0460
Mihai G NeteaDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Menno P J de WintherDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes; Amsterdam Institute for Infection and Immunity, Inflammatory diseases, (AI&II), Amsterdam University Medical Centers, location University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-4038-6636
Thijs J BeldmanDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Arjan W GriffioenAngiogenesis Laboratory, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-8508-4754
Willem J M MulderDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0001-8665-3878
Funding
Using trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primatesP01AI168258 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Abraham Teunissen · 2023 to 2026
$14.7M
NIAID NIH HHS P01 AI168258
6 · The paper itself
Abstract
Hematopoietic bone marrow progenitors are increasingly implicated as an origin of immunosuppression in cancer. We have previously shown that trained immunity induction using nanomedicine potentiates checkpoint blockade therapy. Here, we studied how this approach's induction of trained immunity systemically overcomes the immunosuppressive tumor microenvironment. We found changes in the tumor microenvironment to mirror functional changes in the hematopoietic system in a melanoma mouse model. Single cell sequencing methods disclosed a shift in the tumor-associated macrophage population from immunosuppressive to antitumorigenic. Uniquely, a trained immunity and checkpoint blockade combination therapy mobilized natural killer cells which, in conjunction with the functional changes in the myeloid cell compartment, effectively activated T cells. Last, we established the effectiveness of our approach in mouse models of breast, lung, and pancreatic cancer. Collectively, our data show that the systemic induction of trained immunity rebalances the immune system for effective checkpoint blockade therapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Systemically inducing trained immunity overcomes solid tumors' immunosuppressive microenvironment. · full record | OpenQuestion